U.S. markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.05+0.03 (+0.43%)
At close: 4:00PM EDT

7.05 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close7.02
Open6.99
Bid6.76 x 1300
Ask7.21 x 1200
Day's Range6.86 - 7.11
52 Week Range4.07 - 13.00
Volume239,963
Avg. Volume901,235
Market Cap506.609M
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.55
Earnings DateAug 12, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.59
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
58% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

    First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of investigational new drug (IND)-enabling studies for the Company’s first-in-class therapeutic antibody targeting TDP-43 (TAR DNA-binding protein 43). The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications.Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved this year in the Company’s cutting-edge therapeutic and diagnostic programs targeting TDP-43 – which are amongst the most comprehensive in the field. TDP-43 pathology is strongly associated with cognitive decline and episodic memory loss in neurodegenerative diseases. Effectively slowing or stopping the spread of TDP-43 pathology throughout the brain could provide the first TDP-43 targeted therapeutic approach for treating conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), where almost half of all FTLD cases exhibit TDP-43 pathology with  significant market potential for AC Immune’s TDP-43 antibody. Other indications include limbic-predominant age-related TDP-43 encephalopathy (LATE), and sub-populations of argyrophilic grain disease and Lewy Body Dementia.  Additionally, pathological aggregation of TDP-43 has emerged as an important co-pathology in Alzheimer’s disease linked to disease severity and occurring in ~50% of patients. Recognition that neurodegenerative diseases are driven by a complex interplay of pathologies highlights that successful treatments and cures will likely require combination therapy powered by precision medicine. This diversified approach is pioneered by AC Immune through parallel development of highly selective therapeutics and diagnostics for established targets like Tau and Abeta alongside newer targets such as TDP-43.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “This milestone reinforces AC Immune’s position as a leader in developing novel therapies against neurodegenerative diseases, with our anti-TDP-43 antibody on track to become the first in the world to reach clinical development. Aggregation of pathological forms of TDP-43 is an increasingly validated therapeutic target and a well-established hallmark of neurodegeneration. Initiation of IND-enabling studies for our first-in-class lead anti-TDP-43 antibody is a major step toward addressing pressing unmet need in NeuroOrphan indications.“The Company’s success is driven in part by our proprietary SupraAntigen™ platform, which has already produced therapeutic monoclonal antibody candidates targeting Abeta and Tau that were successfully out-licensed to leading pharmaceutical companies and are currently advancing in multiple Phase 2 clinical studies. Advancement of the anti-TDP-43 antibody further validates the continuing productivity of this platform, which, together with our Morphomer™ platform for small molecule development, are responsible for discovery and development of our maturing pipeline of first-in-class or best-in-class therapeutic and diagnostic candidates.”TDP-43 is an RNA/DNA-binding protein that functions primarily in the nucleus as a regulator of gene transcription and RNA metabolism. TDP-43 pathology has been shown to start from a focal point in the brain and spread to other brain regions with disease progression. Antibody-mediated clearance of pathological TDP-43 therefore represents an attractive strategy for therapeutic intervention – potentially slowing the spread by blocking the ability of pathological TDP-43 to seed aggregation in neighboring healthy cells. The anti-TDP-43 antibody binds all forms of TDP-43 with high affinity and is the only antibody with reported in vivo activity. Proof-of-concept data presented at the 2020 AAT-AD/PD™ Conference demonstrated anti-TDP-43 antibody’s ability to mitigate TDP-43 neuropathology in a mouse model of TDP-43 proteinopathies.About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche group, Eli Lilly and Company, and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com    Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com    Forward looking statementsThis press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

  • GlobeNewswire

    AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool

    AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results presented at AAIC on the Company’s alpha-synuclein positron emission tomography -(PET) tracer program Further validates the ability of AC Immune’s proprietary platforms to accelerate delivery of a new class of promising diagnostics in neurodegenerative diseases LAUSANNE, Switzerland, July 30, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is one of the winners of the Ken Griffin Alpha-synuclein Imaging Competition from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), and is eligible to receive together with its partner USD 3.2 million (CHF 3.1 million).The funding will support the nonclinical and clinical investigation of AC Immune’s proprietary alpha-synuclein-PET tracers, which are the most advanced in the field and could deliver the world’s first imaging agent capable of accurately detecting and monitoring progression of Parkinson’s disease (PD). The clinical arm of the AC Immune project will be conducted in partnership with Prof. Oskar Hansson’s team of world-class researchers at Lund University and Skåne University Hospital in Sweden, which is a recognized Center of Excellence in the field of diagnostics for neurodegenerative diseases. Skåne University Hospital is eligible to receive USD 0.7 million over two years to support this arm of the project.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune is very proud to have attracted repeated support from MJFF over the last five years to advance development of alpha-synuclein-PET tracers. This award follows compelling preclinical results presented this week at the Alzheimer’s Association International Conference (AAIC) on our next generation PET tracer which demonstrates enhanced contrast and alpha-synuclein target specificity, putting our tracer in a strong position to become a first-in-class precision diagnostic tool for Parkinson’s disease (PD). This is a particularly important area of research, and this award really demonstrates the power of our innovative Morphomer™ discovery platform to accelerate the design, development and synthesis of conformation-specific small molecules. An effective alpha-synuclein PET tracer would enable and accelerate the development of new PD therapies as a powerful tool for measuring the effect of novel drugs on alpha-synuclein pathology in the brain.”Jamie Eberling, Ph.D, Vice President of Research at MJFF, said: “The Foundation is committed to the development of an imaging tracer for Parkinson’s. AC Immune has already advanced alpha-synuclein tracers to human clinical testing, and we look forward to its progress as it continues clinical testing and develops new tracers.”The MJFF award for AC Immune’s alpha-synuclein-PET program follows the announcement at this year’s AAT-AD/PD™ conference that the Company’s SupraAntigen™-derived anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat PD and other synucleinopathies. The combined potential of AC Immune’s therapeutic and diagnostic programs is based on the Company’s capabilities in precision medicine and may improve the diagnosis and treatment of alpha-synuclein pathologies, which are also of increasing interest in Alzheimer’s disease (AD) and NeuroOrphan indications.Prof. Oskar Hansson, of Lund University and Skåne University Hospital said: “It would be a huge step forward if we succeed in the development of an accurate and reliable PET method for detection of alpha-synuclein pathology. Such a diagnostic method would be vital for increasing our understanding of the diseases, and more importantly it would facilitate the development of new disease modifying therapies that might halt, or even stop, the progression of PD.”Prof. Pfeifer continued: “Our second generation alpha-synuclein-PET tracer started a first-in-human study last year and plans are in place to start another study to evaluate this tracer in genetic populations and, in parallel, advance a third generation candidate to clinical stage. With this latest award from MJFF, we look forward to advancing this important diagnostic program in collaboration with Prof. Hansson at Lund University and Skåne University Hospital.”About AC Immune’s alpha-synuclein programs Alpha-synuclein misfolding, aggregation and seeding are the molecular basis for the formation of Lewy bodies, a hallmark of PD, multiple system atrophy, and Lewy Body Dementia. Antibody-mediated clearance of pathological alpha-synuclein, including Lewy bodies, represents an attractive strategy for therapeutic intervention. Availability of non-invasive diagnostic tools like PET imaging agents would allow accurate diagnosis and monitoring of disease progression and would potentially enable longitudinal drug efficacy measurements in patients.AC Immune’s PET tracers are derived from the Company’s innovative Morphomer™ discovery platform, which accelerates the design, development and synthesis of conformation-specific small molecules to power successful diagnostic and therapeutic approaches. The Morphomer™ platform has produced multiple small molecules with clinical proof-of-concept that bind selectively to pathological forms of human proteins such as alpha-synuclein and Tau. It is complemented by AC Immune’s SupraAntigen™ platform, which has generated clinically validated monoclonal antibodies and vaccines directed against pathological forms of Tau and Abeta. Together, these platforms have attracted partnerships with leading, global pharmaceutical companies, including Genentech, a member of the Roche group, Janssen Pharmaceuticals and Eli Lilly and Company, and have established AC Immune as an industry leader in the development of novel diagnostic and therapeutic agents for neurodegenerative diseases.About the Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition MJFF is the world's largest nonprofit funder of Parkinson's research with pioneering collaborations across industry, academia and government. This new award from the Ken Griffin Alpha-synuclein Imaging Competition is largely funded through a USD 7.5 million leadership gift from Ken Griffin, Founder and CEO of the Chicago-based global investment firm, Citadel, to incentivize research teams to race to develop a game-changing Parkinson’s diagnostic tool. The USD 10 million Ken Griffin Alpha-synuclein Imaging Competition will be shared between three winning proposals in two rounds of funding with USD 8.5 million initially shared over two years. The final USD 1.5 million will then be awarded to the team that has progressed furthest to develop its program.About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com  US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com   Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

  • GlobeNewswire

    AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent

    Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform for generating highly selective small molecule diagnostics LAUSANNE, Switzerland, July 28, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today reported new data for its next generation alpha-synuclein positron emission tomography-(PET) tracer during an oral presentation at the Alzheimer’s Association International Conference (AAIC) and anticipates advancing its lead compound toward clinical stage development in Q4 2020.The compelling preclinical results demonstrate enhanced contrast and alpha-synuclein target specificity, putting AC Immune’s PET tracer in a strong position to become a first-in-class precision diagnostic tool for Parkinson’s disease (PD). No effective diagnostic agents exist today for PD and other alpha-synucleinopathies, such as multiple system atrophy (MSA), and Lewy Body Dementia (LBD), representing substantial unmet clinical need.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “I am highly encouraged by these results, as they demonstrate AC Immune’s industry-leading expertise in the development of alpha-synuclein-targeting agents. There is increasing recognition of the importance of targeting the right disease pathology at the right time in neurodegenerative diseases, and AC Immune continues to lead the way towards facilitating such an approach through the parallel development of therapeutic and diagnostic agents for important targets such as alpha-synuclein, as well as more well established targets like Tau and Abeta. The data presented at AAIC are a prime example of the power of our Morphomer™ platform to facilitate the rapid optimization of our PET tracers.”Alpha-synuclein misfolding, aggregation and seeding are the molecular basis for the formation of Lewy bodies, a hallmark of PD, MSA, and LBD. The availability of non-invasive diagnostic tools that can distinguish alpha-synucleinopathies from other proteinopathies or normal physiological situations would enable – for the first time – accurate clinical diagnosis, monitoring of disease progression and benefits of drug interventions. ACI-12589 demonstrates significantly increased target occupancy compared to previous-generation candidates as well as a significantly improved signal specificity.AC Immune’s PET tracers are derived from the Company’s innovative Morphomer™ discovery platform, which accelerates the design, development and synthesis of conformation-specific small molecules to power successful diagnostic and therapeutic approaches. The Morphomer™ platform has produced multiple small molecules with clinical proof-of-concept that bind selectively to pathological forms of human proteins such as alpha-synuclein and Tau.Based on proof-of-concept data presented at this year’s AAT-AD/PD™ conference, AC Immune announced that it advanced its SupraAntigen™-derived anti-alpha-synuclein therapeutic antibody candidate from discovery into preclinical development. The combined potential of AC Immune’s therapeutic and diagnostic programs is based on the Company’s capabilities in precision medicine and may improve the diagnosis and treatment of alpha-synuclein pathologies, which are of increasing interest in Alzheimer’s disease (AD) and NeuroOrphan indications.Dr. Capotosti’s presentation was titled Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of a-synucleinopathies. Key highlights from the presentation include: * ACI-3847, a first-generation alpha-synuclein-PET tracer, showed good brain uptake and very low non-specific retention in a first-in-human study in idiopathic PD patients and healthy volunteers * The data on ACI-3847 suggested to test the PET tracer in alpha-synuclein-pathologies with higher levels of alpha-synuclein accumulation * AC Immune’s Morphomer™ platform also led to the discovery of ACI-12589 with excellent target occupancy and signal specificity ex vivo and an expected optimal signal-to-noise ratio in patients * Data presented will show ACI-12589 as a potential first- and best-in-class imaging agent for the diagnosis of PDAbout AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com    Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.